TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23890316

Group type: EXPERIMENTAL
Intervention: All Children in Focus program (intervention group)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 600
Study: 21251896

Group type: EXPERIMENTAL
Intervention: 50 mg of MET (n = 19) for 4 weeks followed by 100 mg MET for 4 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: 5 mg of NEB (n = 22) for 4 weeks followed by 10 mg NEB for 4 weeks
Number of subjects: 41
Study: 18494632

Group type: EXPERIMENTAL
Intervention: Coban 2 Layer Compression System
Number of subjects: 81

Group type: COMPARATOR
Intervention: Profore Compression System
Number of subjects: 81
Study: 16253414

Group type: EXPERIMENTAL
Intervention: Urapidil (initial dose of 12.5-25mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Dihydralazine (uniform initial dose of 5mg)
Number of subjects: 42
Study: 14649341

Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine 0.25% plus intravenous morphine 2 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intraperitoneal bupivacaine 0.25%
Number of subjects: 90

Group type: COMPARATOR
Intervention: Physiological saline (control group)
Number of subjects: 90
Study: 10988107

Group type: EXPERIMENTAL
Intervention: Paroxetine hydrochloride
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 9007717

Group type: EXPERIMENTAL
Intervention: Single dose UDCA (10 mg kg‐1 day‐1) at bed time
Number of subjects: 27

Group type: COMPARATOR
Intervention: Multiple dose UDCA (10 mg kg‐1 day‐1) in three divided doses with meals
Number of subjects: 27
Study: 1829918

Group type: EXPERIMENTAL
Intervention: IDA/ARA
Number of subjects: 255

Group type: COMPARATOR
Intervention: DNR/ARA
Number of subjects: 255
Study: 6751536

Group type: EXPERIMENTAL
Intervention: Fentiazac 100 mg four times a day for one week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31682976

Group type: EXPERIMENTAL
Intervention: Fosamprenavir administered during MMC phase II
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fosamprenavir administered during MMC phase I
Number of subjects: 6
Study: 31159753

Group type: EXPERIMENTAL
Intervention: Conditional cash transfer (CCT) program
Number of subjects: 1254

Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 1254
Study: 28624486

Group type: EXPERIMENTAL
Intervention: Optimal risk factor control (0 risk factors)
Number of subjects: 34736

Group type: EXPERIMENTAL
Intervention: Optimal risk factor control (1 risk factor)
Number of subjects: 34736

Group type: EXPERIMENTAL
Intervention: Optimal risk factor control (2 risk factors)
Number of subjects: 34736

Group type: COMPARATOR
Intervention: 3 or 4 risk factors
Number of subjects: 34736
Study: 26422605

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 69
Study: 23863224

Group type: EXPERIMENTAL
Intervention: Multifaceted activating performance feedback strategy
Number of subjects: 25552

Group type: COMPARATOR
Intervention: Standard quarterly benchmark reports
Number of subjects: 25552
Study: 22562389

Group type: EXPERIMENTAL
Intervention: Subcutaneous adalimumab injections
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intraarticular glucocorticoid injections
Number of subjects: 18
Study: 18618363

Group type: EXPERIMENTAL
Intervention: Herpifix
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dummy
Number of subjects: 30
Study: 17365463

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) for detecting deep myometrial invasion
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI) for detecting cervical invasion
Number of subjects: 101

Group type: COMPARATOR
Intervention: Histopathologic evaluation (as control)
Number of subjects: 101
Study: 15471824

Group type: EXPERIMENTAL
Intervention: Coregistration of SPECT and CT-derived attenuation maps
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Semiquantitative analysis
Number of subjects: 140
Study: 11718167

Group type: EXPERIMENTAL
Intervention: Leuprorelin
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Triptorelin
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Leuprorelin and triptorelin
Number of subjects: 300
Study: 10205747

Group type: EXPERIMENTAL
Intervention: D allele frequency in type 2 DM patients with MI (64%)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: DD homozygotes prevalence in type 2 DM patients with MI (41%)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: D allele (RR 1.43)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: DD genotype (RR 1.75)
Number of subjects: 75
Study: 8172482

Group type: EXPERIMENTAL
Intervention: Bepridil (300 mg/day after a loading dose of 900 mg on D1, 500 mg on D2 and D3)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Diltiazem (360 mg/day)
Number of subjects: 208
Study: 3075350

Group type: EXPERIMENTAL
Intervention: Mefloquine (750 mg) and artemether (600 mg by injection, 200 mg initially and 100 mg every 12 h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Quinine (10 mg/kg orally every 8 h for 7 d)
Number of subjects: 60
Study: 31470444

Group type: EXPERIMENTAL
Intervention: DAPT plus high-dose edoxaban (60 mg once daily)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: DAPT plus low-dose edoxaban (30 mg once daily)
Number of subjects: 75

Group type: COMPARATOR
Intervention: DAPT only
Number of subjects: 75
Study: 30223728

Group type: EXPERIMENTAL
Intervention: Sitting with 3 min bouts of light-intensity exercise while standing every 30 min
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sitting with 3 min of walking every 30 min
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sitting for 8 h uninterrupted
Number of subjects: 19
Study: 28827258

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT) administered via enema, two times per week for 6 weeks.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline control administered via enema, two times per week for 6 weeks.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 50
Study: 25618566

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the primary auditory cortex (2 mA for 20 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham stimulation (no stimulation except initial ramp-up for 30 s)
Number of subjects: 12
Study: 24366792

Group type: EXPERIMENTAL
Intervention: Proximal femoral locking plate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dynamic hip screw (DHS)
Number of subjects: 40
Study: 21628697

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: High-dose aspirin
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 19108787

Group type: EXPERIMENTAL
Intervention: Milnacipran 100 mg/d
Number of subjects: 1196

Group type: EXPERIMENTAL
Intervention: Milnacipran 200 mg/d
Number of subjects: 1196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1196
Study: 16634956

Group type: EXPERIMENTAL
Intervention: 800 mg ibuprofen arginine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 14525716

Group type: EXPERIMENTAL
Intervention: Residential multifactorial cardiac rehabilitation
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Outpatient multifactorial rehabilitation
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Stress management
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard coronary rehabilitation
Number of subjects: 132
Study: 10858985

Group type: EXPERIMENTAL
Intervention: Lidocaine (preinhalation)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (saline, preinhalation)
Number of subjects: 12
Study: 8826510

Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg) + bromazepan (3 mg)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg) + placebo
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Bromazepan (3 mg) + placebo
Number of subjects: 164

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 164
Study: 1425546

Group type: EXPERIMENTAL
Intervention: 15-session prevention program
Number of subjects: 3153

Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 3153
Study: 6731021

Group type: EXPERIMENTAL
Intervention: Omnipaque 350 mg I/ml
Number of subjects: 40

Group type: COMPARATOR
Intervention: Urografin 370 mg I/ml
Number of subjects: 40
Study: 30251154

Group type: EXPERIMENTAL
Intervention: Unprotected weight-bearing as tolerated
Number of subjects: 115

Group type: COMPARATOR
Intervention: Protected weight-bearing
Number of subjects: 115

Group type: COMPARATOR
Intervention: Unprotected non-weight-bearing
Number of subjects: 115
Study: 31126551

Group type: EXPERIMENTAL
Intervention: Urtica dioica 450 mg/day and acupuncture 11 sessions (A)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Acupuncture and placebo (B)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sham acupuncture and Urtica dioica (C)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham acupuncture and placebo (D)
Number of subjects: 72
Study: 27601217

Group type: EXPERIMENTAL
Intervention: Beta-alanine (6.4g/day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (dextrose, same dosage)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Beta-alanine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: COMPARATOR
Intervention: Beta-alanine and Placebo
Number of subjects: 23
Study: 25816342

Group type: EXPERIMENTAL
Intervention: Chlorine plus safe storage
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Safe storage
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1800
Study: 24004044

Group type: EXPERIMENTAL
Intervention: Sensor-augmented insulin pump (SAP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Multiple daily injection (MDI) therapy
Number of subjects: 60
Study: 21726440

Group type: EXPERIMENTAL
Intervention: HIP Programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 19236409

Group type: EXPERIMENTAL
Intervention: Keyhole Limpet Hemocyanin (KLH) 100 microg adsorbed to aluminium hydroxide
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Keyhole Limpet Hemocyanin (KLH) 10 microg intra-dermally
Number of subjects: 32

Group type: COMPARATOR
Intervention: Matching placebo (alum alone)
Number of subjects: 32
Study: 16930768

Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study: 14644857

Group type: EXPERIMENTAL
Intervention: Corticosteroids and NSAIDs
Number of subjects: 76
Study: 12785090

Group type: EXPERIMENTAL
Intervention: K-Four four-layer bandage system
Number of subjects: 10
Study: 8831474

Group type: EXPERIMENTAL
Intervention: Elbow splinting only (Group A)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Local steroid injection plus elbow splinting (Group B)
Number of subjects: 10
Study: 1429485

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day, 40 mg/day, 60 mg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 4043661

Group type: EXPERIMENTAL
Intervention: Bacitracin (80,000 U/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vancomycin (500 mg/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 42
Study: 31254431

Group type: EXPERIMENTAL
Intervention: C-SVEST scale
Number of subjects: 1442
Study: 30520413

Group type: EXPERIMENTAL
Intervention: Modified self‐management plan advising temporary quadrupling of inhaled corticosteroid dose
Number of subjects: 1922

Group type: COMPARATOR
Intervention: Usual-care self‐management plan
Number of subjects: 1922

Group type: EXPERIMENTAL
Intervention: Modified self‐management plan
Number of subjects: 1922
Study: 27255079

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 (6 × 10(9) cfu/day)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 25283697

Group type: EXPERIMENTAL
Intervention: VEN‐XR
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 22760494

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 135

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 135
Study: 20578203

Group type: EXPERIMENTAL
Intervention: Prediabetes identified by fasting plasma glucose (FPG) alone
Number of subjects: 1677

Group type: COMPARATOR
Intervention: Normal glucose tolerance (NGT) at baseline
Number of subjects: 1677

Group type: EXPERIMENTAL
Intervention: Risk factors measured (elevated A(1c), 2‐h PG, fasting insulin (FI), albuminuria, obesity)
Number of subjects: 1677

Group type: EXPERIMENTAL
Intervention: Younger age, elevated FI, less physical activity
Number of subjects: 1677
Study: 18037602

Group type: EXPERIMENTAL
Intervention: AIME (Integrated Medical Encounter)
Number of subjects: 120

Group type: COMPARATOR
Intervention: non-AIME (control group)
Number of subjects: 120
Study: 15921608

Group type: EXPERIMENTAL
Intervention: Typhoid Vi vaccine
Number of subjects: 96476

Group type: COMPARATOR
Intervention: Meningococcal A vaccine
Number of subjects: 96476
Study: 11813173

Group type: EXPERIMENTAL
Intervention: Prophylactic G-CSF administration after chemotherapy intensification
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no G-CSF)
Number of subjects: 46
Study: 10400415

Group type: EXPERIMENTAL
Intervention: GM‐CSF at a dose of 3 microg/kg s.c. on days 1‐2, rhEpo at a dose of 60 U/kg s.c. on days 3‐5, repeated for a total of 6 weeks, with dose increase to 120 U/kg if Hb rise not achieved.
Number of subjects: 19
Study: 7740017

Group type: EXPERIMENTAL
Intervention: Community-based smoking cessation intervention in Den Bosch
Number of subjects: 1093

Group type: COMPARATOR
Intervention: Control city (Apeldoorn)
Number of subjects: 1093
Study: 2044550

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 7267677

Group type: EXPERIMENTAL
Intervention: Minaprine (100 mg per day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 31060591

Group type: EXPERIMENTAL
Intervention: Ringer's acetate (RA)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Ringer's lactate (RL)
Number of subjects: 148
Study: 27697911

Group type: EXPERIMENTAL
Intervention: Alcohol treatment (intoxicated)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo treatment (control)
Number of subjects: 41
Study: 26388707

Group type: EXPERIMENTAL
Intervention: p-synephrine (S; 100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: p-synephrine + caffeine (SCF; 100 mg of p-synephrine plus 100 mg of caffeine)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 12
Study: 23903811

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine dose reduction (20% reduction weekly for 10 weeks)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no change in morphine dose)
Number of subjects: 15
Study: 20963533

Group type: EXPERIMENTAL
Intervention: Ceramic-on-ceramic THAs
Number of subjects: 512

Group type: COMPARATOR
Intervention: Metal-on-polyethylene THAs
Number of subjects: 512
Study: 19712598

Group type: EXPERIMENTAL
Intervention: Pharmaceutical intervention programme
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 185
Study: 17439439

Group type: EXPERIMENTAL
Intervention: INFANIB screening tool
Number of subjects: 6150
Study: 12435255

Group type: EXPERIMENTAL
Intervention: Lower BP goal (mean arterial pressure 92 mm Hg or less)
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Usual BP goal (mean arterial pressure 102 to 107 mm Hg)
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: Ramipril (2.5‐10 mg/d)
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Metoprolol (50‐200 mg/d)
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Amlodipine (5‐10 mg/d)
Number of subjects: 1094
Study: 10626558

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a dose of 0.1 IU/kg/day (0.033 mg/kg/day) for 2 years (Group A)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a dose of 0.2 IU/kg/day (0.066 mg/kg/day) during the second year (Group B)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment restarted at a dose of 0.1 IU/kg/day (0.033 mg/kg/day) after a 6-month break
Number of subjects: 18

Group type: COMPARATOR
Intervention: Not applicable (control group, untreated for the first year)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Not applicable (GH treatment withdrawn)
Number of subjects: 18
Study: 7795941

Group type: EXPERIMENTAL
Intervention: Physical practice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mental practice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational practice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptual discrimination task practice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discrimination of a nonspatial version of the criterion motion
Number of subjects: 0
Study: 1951859

Group type: EXPERIMENTAL
Intervention: Oral metrifonate (10 mg/kg for three doses each year)
Number of subjects: 2493

Group type: EXPERIMENTAL
Intervention: Praziquantel therapy (40 mg/kg as a single dose each year)
Number of subjects: 2493

Group type: COMPARATOR
Intervention: Control group (no specific control intervention mentioned)
Number of subjects: 2493
Study: 7197489

Group type: EXPERIMENTAL
Intervention: Droperidol, 2.5 mg IM
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 100 mg IM
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 29805252

Group type: EXPERIMENTAL
Intervention: Active buprenorphine 5 µg/hour
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Active buprenorphine
Number of subjects: 162
Study: 28099979

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone lactate (low dose: 20 mcg/kg bolus followed by 0.2 mcg/kg/minute)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous milrinone lactate (standard dose: 50 mcg/kg bolus followed by 0.5 mcg/kg/minute)
Number of subjects: 6
Study: 26268533

Group type: EXPERIMENTAL
Intervention: Agomelatine (25 mg)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Agomelatine (50 mg)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 23239793

Group type: EXPERIMENTAL
Intervention: Soft diet (SD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clear liquid diet (CLD)
Number of subjects: 60
Study: 21606084

Group type: EXPERIMENTAL
Intervention: Optimized echo-guided CRT
Number of subjects: 186

Group type: COMPARATOR
Intervention: RV apical pacing
Number of subjects: 186
Study: 18444738

Group type: EXPERIMENTAL
Intervention: Subliminal stimulus exposure with a focus on evaluative tone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primed concepts with extreme evaluative meaning
Number of subjects: 0
Study: 16572266

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15284369

Group type: EXPERIMENTAL
Intervention: Isolated soy protein (ISP)
Number of subjects: 14
Study: 10405745

Group type: EXPERIMENTAL
Intervention: Injection of 2 mL/kg of 300 mg iodine/mL contrast material at 5 mL/sec (Group 1)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Injection of 2 mL/kg of 300 mg iodine/mL contrast material at 3 mL/sec (Group 2)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Injection of 1.5 mL/kg of 300 mg iodine/mL contrast material at 5 mL/sec (Group 3)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Injection of 1.5 mL/kg of 300 mg iodine/mL contrast material at 3 mL/sec (Group 4)
Number of subjects: 126
Study: 7563045

Group type: EXPERIMENTAL
Intervention: Belief and information intervention
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Belief intervention
Number of subjects: 405

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 405
Study: 2127325

Group type: EXPERIMENTAL
Intervention: CPS recommendations accepted 100% of the time
Number of subjects: 110

Group type: COMPARATOR
Intervention: CPS recommendations accepted less than 100% of the time
Number of subjects: 110
Study: 7373255

Group type: EXPERIMENTAL
Intervention: Vigorous group patient education and family physician appointments
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Supportive individualized psychosocial counseling and family physician appointments
Number of subjects: 123

Group type: COMPARATOR
Intervention: Family physician appointments only (baseline medical care)
Number of subjects: 123
Study: 31811673

Group type: EXPERIMENTAL
Intervention: Ibuprofen plus acetaminophen
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ibuprofen plus placebo
Number of subjects: 120
Study: 31870414

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced spectral mammography (CESM)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Conventional breast imaging techniques
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: CESM
Number of subjects: 528
Study: 28410922

Group type: EXPERIMENTAL
Intervention: Artichoke Leaf Extract (ALE) 1800 mg (four tablets per day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (cornstarch, lactose, and avicel, four tablets per day)
Number of subjects: 80
Study: 27681579

Group type: EXPERIMENTAL
Intervention: Dovitinib capsule (500 mg once daily on a 5-days-on/2-days-off schedule)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Dovitinib tablet (500 mg once daily on a 5-days-on/2-days-off schedule)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Dovitinib (both formulations)
Number of subjects: 173
Study: 25826793

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 33
Study: 22154243

Group type: EXPERIMENTAL
Intervention: Monophasic preparation containing 30μg ethinylestradiol and 150μg desogestrel (DG/EE)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Monophasic preparation containing 30μg ethinylestradiol and 150μg levonogestrel (LNG/EE)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both COCs (DG/EE and LNG/EE)
Number of subjects: 44